ABSTRACT
The cost-effective synthesis of enantiopure compounds is and will continue to be a challenge for the fine chemical industry (see Chapter 1
)
. For 2003, the revenues generated by fine chemical companies via application of chiral technology for pharmaceutical and agrochemical intermediates was estimated to be $8 billion with an annual growth of approximately 11%.
